Cannabis Report
Home > Boards > US Listed > Biotechs >

Axsome Therapeutics (AXSM)

AXSM RSS Feed 		Add AXSM Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/29/2018 3:39:14 PM - Followers: 20 - Board type: Free - Posts Today: 0

Undiscovered and massive undervalued Biotech Stock with many Big News on the way . Axsome has 7 Phase 3 in various indication targeting very large Markets including Alzheimer and Depression .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered Stock could be the next 10 bagger if only one of their 5 Phase 3 program is successful .GL


Axsome (AXSM)

Market-Cap: $83 Million
Cash: $41 Million (cash runway into the second quarter of 2019)
Price:$3.60

Shares Out: 23 Million


New Presentation Mid November
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf


Anticipated Near-Term Clinical Milestones

• Clinical Trial Readouts:

•Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)

•Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)

•Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)



7 x Phase 3 Programs in Pipeline :

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track) ---7M patients in the U.S.


AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.


AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.


AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---No approved medication = unmet medical need. 2M patients in the U.S.


AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.


AXS-06(MoSEIC™ Mx + Eso) Acute and Chronic Pain Phase 3 Ready = 120M NSAID TRx per year in the U.S.


AXS-07 (meloxicam and rizatriptan) for the Treatment of Migraine Phase 3 Ready = Migraine attacks are disabling and affect more than 37 million Americans





MAJOR SHAREHOLDERS :

Herriott Tabuteau, MD 7 351 729 31,1%
Fidelity Management & Research Co. 1 516 212 6,42%
JPMorgan Asset Management (UK) Ltd. 1 432 456 6,07%
Sabby Capital LLC 1 408 000 5,96%
Laurence W. Lytton 1 300 692 5,51%
Royce & Associates LP 881 000 3,73%
Mark Coleman, MD 647 998 2,75%
Sphera Funds Management Ltd. 501 000 2,12%
The Vanguard Group, Inc. 418 022 1,77%
Stifel Trust Co., NA 415 279 1,76%









the latest stock market analyst ratings:

Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.







Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You
>>>>>>>>>>>>>>>>>>>>>How to Prevent your Shares Holdings from being Shorted<<<<<<<<<<<<<<<<<<<<<<
http://www.contracts-for-difference.com/Borrowing-lending-shares.html
 
Cannabis Report
AXSM
Current Price
Volume:
Bid Ask Day's Range
AXSM Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AXSM News: Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agita... 09/19/2018 07:00:00 AM
AXSM News: Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference 08/28/2018 07:00:00 AM
AXSM News: Securities Registration: Employee Benefit Plan (s-8) 08/13/2018 05:26:45 PM
AXSM News: Quarterly Report (10-q) 08/08/2018 04:15:33 PM
AXSM News: Current Report Filing (8-k) 08/08/2018 04:09:11 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#112   20th Annual Rodman & Renshaw Global Investment Conference chainma1l 08/29/18 03:39:14 PM
#111   Short Interest on AXSM.....750,000 shares short conix 06/14/18 04:10:42 PM
#110   AXSM needs to break through the 200 DMA conix 06/11/18 06:34:06 PM
#109   Should have 5 phase 3 trials going here chainma1l 04/26/18 04:28:32 PM
#108   $3.10s up volume picking up stock1ace1 04/26/18 12:59:33 PM
#107   AXSM $3.00 *** Phase 3 News stock1ace1 04/26/18 11:07:00 AM
#106   Get that phase 3 for AXS-07 underway! chainma1l 03/14/18 09:50:02 AM
#105   AXSM cheat sheet Golden_Cross 03/12/18 10:23:26 PM
#104   Money flow on the rise Golden_Cross 03/12/18 10:22:47 PM
#103   RSI breaking into bullish territory Golden_Cross 03/12/18 10:22:28 PM
#102   Chart looking good Golden_Cross 03/12/18 10:21:46 PM
#101   Axsome Therapeutics Reports Fourth Quarter and Full Year Golden_Cross 03/12/18 10:19:46 PM
#100   I think yesterday’s bounce off 2.75 was a Mr_Popeye 01/18/18 10:21:27 AM
#99   Spent about half of what I wanted to chainma1l 01/18/18 10:14:06 AM
#98   Absolutely agree. Patiently waiting for an entry. Huge Mr_Popeye 01/17/18 02:43:48 PM
#97   AXSM = Market Cap $70 Million / Cash BioSpecialist 01/17/18 01:54:48 PM
#96   This “overreaction” is still going down with no Mr_Popeye 01/16/18 12:58:17 PM
#95   I agree about the overreaction. Bummer that chainma1l 01/12/18 11:04:58 AM
#94   this is WAY overold. yes, 1 trial has otclife 01/11/18 12:05:16 PM
#93   Welp, that sucks. Luckily my gut told me djmurdock 01/09/18 12:14:15 PM
#92   Batting .500. CPRS would have been the chainma1l 01/09/18 07:43:02 AM
#91   Fair enough, thx djmurdock 01/08/18 10:25:00 AM
#90   Optimistic? Yes. Confident? I have chainma1l 01/08/18 10:19:13 AM
#89   How confident are you guys in the upcoming djmurdock 01/05/18 06:07:37 PM
#88   "late December 2017 or early January 2018" chainma1l 01/04/18 04:47:38 PM
#87   Up she goes BioSpecialist 12/28/17 11:47:14 AM
#86   Chart: 10bags 12/28/17 10:28:24 AM
#85   we are in a big triangle since years. 10bags 12/28/17 10:13:05 AM
#84   runup to phase 3 results has just begun...GL BioSpecialist 12/28/17 09:47:38 AM
#83   52900 on the bid for 5.2 dollar ! Mauriziomh 12/27/17 10:41:46 AM
#82   Looks like breakout is on the way ..2x BioSpecialist 12/26/17 11:22:01 AM
#81   it's getting ready for a break out arbytrader 12/26/17 10:51:12 AM
#80   5 Top Biotech Penny Stocks to Buy with BioSpecialist 12/22/17 01:34:02 PM
#79   Got me some today... europtiger 12/22/17 01:11:53 PM
#78   If the volume was higher, I would suspect chainma1l 12/22/17 12:52:37 PM
#77   $30+ if more than one successful ph 3. chainma1l 12/22/17 12:36:28 PM
#76   $10++ if phase 3 results is successful BioSpecialist 12/22/17 10:53:11 AM
#75   Penny? Inflation has really been sneaky. chainma1l 12/22/17 10:36:15 AM
#74   Biotech Penny Stocks to Buy for January, No. BioSpecialist 12/22/17 10:17:20 AM
#73   $5++ imminent BioSpecialist 12/21/17 10:24:32 AM
#72   2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME BioSpecialist 12/20/17 12:49:17 PM
#71   Great news out! BVDP 12/14/17 07:34:38 AM
#70   This one will blow before 2018. 2 results BVDP 12/07/17 05:26:46 AM
#69   That was pretty painless for shareholders. Maybe chainma1l 12/06/17 09:40:43 AM
#68   I knew the cash raise was coming, I chainma1l 12/01/17 10:06:54 AM
#67   I'm really amazed AXSM hasn't garnered more attention. chainma1l 11/28/17 10:13:47 AM
#66   Options. chainma1l 08/09/17 10:14:44 AM
#65   Large insider buy djmurdock 08/08/17 05:05:23 PM
#64   Ladenburg Thalmann raised its price target on Axsome BioSpecialist 07/26/17 08:15:19 AM
#63   I'm not sure why AXSM isn't higher at chainma1l 07/25/17 10:12:26 AM
PostSubject
© 2018 InvestorsHub.com, Inc.




Ticker News is disabled